Molecularly targeted agents (MTAs), such as imatinib in chronic myelogenous leukemia or trastuzumab in Her‐2/neu‐positive breast cancer, have shown significant prolongation of overall survival in the corresponding malignancies and sometimes, cures.1 Here, ERBB2 is linked to breast carcinoma.